
    
      The study will be a 16 to 18-week study, including a 2 to 4-week screening period, followed
      by a 12-week double-blind, randomized, placebo-controlled treatment Period, and a 2-week
      follow-up period. Subjects eligible for the study will be randomized to receive either
      NYX-458 or placebo.
    
  